NASDAQ : IOVA
Iovance Biotherapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 9.56 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.33B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.61B |
| Enterprise Value | 3.35B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 452.97M |
| Shares Outstanding | 452.97M |
| Shares Change (YoY) | +29.62% |
| Shares Change (QoQ) | +7.57% |
| Owned by Insiders (%) | 6.56% |
| Owned by Institutions (%) | 58.00% |
| Float | 394.31M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.07 |
| Forward PS | 6.90 |
| PB Ratio | 5.22 |
| P/TBV Ratio | 7.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 10.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.35 |
| Quick Ratio | 3.74 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -40.36% |
| Return on Assets (ROA) | -20.31% |
| Return on Invested Capital (ROIC) | -24.14% |
| Return on Capital Employed (ROCE) | -36.62% |
| Weighted Average Cost of Capital (WACC) | 8.75% |
| Revenue Per Employee | $333,302 |
| Profits Per Employee | -$296,941 |
| Employee Count | 975 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 3.18 |
Taxes
| Measure | Value |
|---|
| Income Tax | -4.26M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.84 |
| 52-Week Price Change | +300.00% |
| 50-Day Moving Average | 11.36 |
| 200-Day Moving Average | 5.87 |
| Relative Strength Index (RSI) | 28.77 |
| Average Volume (20 Days) | 14,940,470 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 58.93M |
| Short Previous Month | 64.83M |
| Short % of Shares Out | 13.01% |
| Short % of Float | 14.94% |
| Short Ratio (days to cover) | 3.26 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 324.97M |
| Gross Profit | 157.29M |
| Operating Income | -296.17M |
| Pretax Income | -293.78M |
| Net Income | -289.52M |
| EBITDA | -259.60M |
| EBIT | -296.17M |
| Loss Per Share | -$0.71 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 297.67M |
| Total Debt | 46.00M |
| Net Cash | 251.67M |
| Net Cash Per Share | $0.56 |
| Equity (Book Value) | 736.05M |
| Book Value Per Share | 1.62 |
| Working Capital | 357.41M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -264.18M |
| Capital Expenditures | -32.21M |
| Depreciation & Amortization | 36.56M |
| Net Borrowing | n/a |
| Free Cash Flow | -296.40M |
| FCF Per Share | -$0.65 |
Margins
| Measure | Value |
|---|
| Gross Margin | 48.40% |
| Operating Margin | -91.14% |
| Pretax Margin | -90.40% |
| Profit Margin | -89.09% |
| EBITDA Margin | -79.89% |
| EBIT Margin | -91.14% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -29.62% |
| Shareholder Yield | -29.62% |
| Earnings Yield | -8.87% |
| FCF Yield | -8.24% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $14.20 |
| Price Target Difference | 78.39% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 51.77% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 26, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.81 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |